How we treat a hemophilia A patient with a factor VIII inhibitor.
about
Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia ADangerous liaisons: how the immune system deals with factor VIIIFactor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin.Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXB-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.Hemophilia care in India: a review and experience from a tertiary care centre in uttar pradesh.Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a miceThe use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.Factor VIII inhibitors: a 50-year perspective.Immune tolerance induction for patients with severe hemophilia A: a critical literature review.Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceStrategies for reducing inhibitor formation in severe haemophilia.New and improved AAVenues: current status of hemophilia B gene therapy.A close insight to factor VIII inhibitor in the congenital hemophilia A.The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres.Oral surgery-associated postoperative bleeding in haemophilia patients - a tertiary centre's two decade experience.Attempts to treat patients with hemophilia, the "royal disease".Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.B-cell tolerance in transplantation: is repertoire remodeling the answer?Post splenectomy fatal pulmonary embolism in a patient with moderate hemophilia a.Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex.B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells.Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia.Repression of Factor VIII Inhibitor Development with Apoptotic Factor VIII-expressing Embryonic Stem Cells.Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment.Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Inhibitor development: The last enemy to be defeated in hemophilia A and B.Clinicohematologic Profile of Patients With Factor VIII Inhibitors: A Case Series.Influence of class I and II HLA alleles on inhibitor development in severe haemophilia A patients from the south of Brazil.Hemostatic treatment using factor VIII concentrates for neutralizing high-responding inhibitors prior to CVAD insertion for immune-tolerance induction therapy.Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A.How I treat inhibitors in haemophilia.Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.
P2860
Q26738507-75FA5255-9CEB-4A71-AFA2-AB694FCB3E0EQ27000818-D6947C80-C455-46EB-854F-33246545F103Q33394560-ECB913B2-DAB8-4A1F-A6A6-C433CAC8D3A4Q33608230-E177F7EA-4E6B-491E-9A7C-AB95A599E155Q34159016-A151715C-A428-4215-99BD-35E5CF8B65CAQ34629805-830B7A19-FC9D-4A8E-87D6-379F5E9416BEQ35069871-D3F8335E-04D8-41CF-877F-FDB41DD1EB4CQ35163225-DC5920DF-EE43-44D7-924E-98321E4B8F4CQ37174443-61D99C46-1939-4917-B566-75BCBDCB0058Q37790614-9FEE3BC7-3F42-4875-8C80-92F6851D3BBEQ37876956-75602B50-BFC8-4CBC-A5E4-8461DFC2B05BQ37912059-17852772-74D9-43FB-8966-ADCBD4C20508Q37927122-0F0F97CC-B204-4424-9865-F2F80208A4F7Q38038332-489C7CC5-EC8C-4419-983B-3BBC084246A6Q38101041-52D04FA4-395B-44CA-8B8F-A2D68D414E36Q38308222-5C25387D-478C-4DFB-8921-5AC255A14CBEQ38622440-C3AB93B5-D2C5-485B-9644-A6B88AD73CB0Q38883211-7A255FAF-9EB1-4C98-9B35-70BE84C8CD71Q39475869-5EC9E080-927C-446E-8AB2-4490732E1C72Q39600375-96958DC9-5D73-4C1E-A17B-331A6B24A19FQ41592459-ACAA1AB2-24D4-4AD5-A208-0861242DEEC2Q41731487-41DB4985-0979-4F3F-AA29-274C66AE0CE9Q41876490-03005600-A984-4368-8980-0D30AF84BBA9Q41924275-5616E657-5B41-4A9A-B52C-16CB924DB002Q42038591-2386D096-2125-41E9-9159-84CA1902B388Q42058402-29190050-2A39-46B9-B632-526DB225DFBAQ42257925-16E8AEA8-4DCC-48E8-AE0B-4E8800384E89Q42502298-A13AC070-3758-483D-8D1B-EEECF192F3BBQ42722916-0058D4C7-2046-41B0-8AEB-89276E7180E4Q43080896-FCD5F5FA-21B8-48B9-8BD0-73B93DC0FCCDQ45260428-D8F088AC-75F0-4C26-A1BC-DE117FF13101Q45838031-27A19755-AA62-48BE-BB59-75D9D62A3666Q45864390-8BDED348-EF39-404D-8DB1-86156F10C861Q45868103-D11C4B55-CF9E-46D4-90E0-3E2540BE94A1Q45871512-83FD016E-3F09-4C07-84C0-2AF7F258A855Q45871587-6C1DD831-BEDD-46AE-B522-BB5CB651B91BQ45875675-FD4A5FFE-1C22-45C3-B470-18E4ED7DB7F5Q45879927-49C28F02-DE1A-4421-83DF-01558F0CEA67Q45882083-A876069D-180C-4CBD-B80E-FC47C9CF15A5
P2860
How we treat a hemophilia A patient with a factor VIII inhibitor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
How we treat a hemophilia A patient with a factor VIII inhibitor.
@en
How we treat a hemophilia A patient with a factor VIII inhibitor.
@nl
type
label
How we treat a hemophilia A patient with a factor VIII inhibitor.
@en
How we treat a hemophilia A patient with a factor VIII inhibitor.
@nl
prefLabel
How we treat a hemophilia A patient with a factor VIII inhibitor.
@en
How we treat a hemophilia A patient with a factor VIII inhibitor.
@nl
P921
P1433
P1476
How we treat a hemophilia A patient with a factor VIII inhibitor.
@en
P2093
Christine L Kempton
Gilbert C White
P356
10.1182/BLOOD-2008-06-160432
P407
P577
2008-09-26T00:00:00Z